Abstract
Glioblastoma is a disease with poor outcomes despite standard therapy. Specific targeting of the DNA damage response is a strategy that is becoming increasingly employed in oncology and has intriguing potential for improving outcomes in glioblastoma. DNA damage targeting has implications for improving current therapy as well as the potential to leverage inherent differences in glioblastoma cells to widen the therapeutic window.
Similar content being viewed by others
References
Jemal A, Siegel R, Xu J et al (2010) Cancer statistics, 2010. CA Cancer J Clin 60:277–300
Louis DN, Ohgaki H, Wiestler OD et al (2007) WHO Classification of tumours of the central nervous system. IARC Press, Lyon
Stupp R, Hegi ME, Mason WP et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459–466
Kennedy RD, D’Andrea AD (2006) DNA repair pathways in clinical practice: lessons from pediatric cancer susceptibility syndromes. J Clin Oncol 24:3799–3808
Lengauer C, Kinzler KW, Vogelstein B (1998) Genetic instabilities in human cancers. Nature 396:643–649
Eisen JA, Hanawalt PC (1999) A phylogenomic study of DNA repair genes, proteins, and processes. Mutat Res 435:171–213
Hoeijmakers JH (2001) Genome maintenance mechanisms for preventing cancer. Nature 411:366–374
Weinberg RA (2007) The biology of cancer. Garland Science, New York
Harper JW, Elledge SJ (2007) The DNA damage response: ten years after. Mol Cell 28:739–745
Zhou B-BS, Bartek J (2004) Targeting the checkpoint kinases: chemosensitization versus chemoprotection. Nat Rev Cancer 4:216–225
Dai Y, Grant S (2010) New insights into checkpoint kinase 1 in the DNA damage response signaling network. Clin Cancer Res 16:376–383
Kastan MB, Bartek J (2004) Cell-cycle checkpoints and cancer. Nature 432:316–323
Gerson SL (2004) MGMT: its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer 4:296–307
Bryant HE, Schultz N, Thomas HD et al (2005) Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434:913–917
Farmer H, McCabe N, Lord CJ et al (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434:917–921
McCabe N, Turner NC, Lord CJ et al (2006) Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-Ribose) polymerase inhibition. Cancer Res 66:8109–8115
Rouse J, Jackson SP (2002) Interfaces between the detection, signaling, and repair of DNA damage. Science 297:547–551
Kao J, Rosenstein BS, Peters S et al (2005) Cellular response to DNA damage. Ann N Y Acad Sci 1066:243–258
Lindahl T, Wood RD (1999) Quality control by DNA repair. Science 286:1897–1905
Jiricny J (2006) The multifaceted mismatch-repair system. Nat Rev Mol Cell Biol 7:335–346
Kinsella TJ (2009) Coordination of DNA mismatch repair and base excision repair processing of chemotherapy and radiation damage for targeting resistant cancers. Clin Cancer Res 15:1853–1859
Comprehensive genomic characterization defines human glioblastoma genes and core pathways (2008). Nature 455:1061–1068
Aebi S, Fink D, Gordon R et al (1997) Resistance to cytotoxic drugs in DNA mismatch repair-deficient cells. Clin Cancer Res 3:1763–1767
Fink D, Aebi S, Howell SB (1998) The role of DNA mismatch repair in drug resistance. Clin Cancer Res 4:1–6
Hunter C, Smith R, Cahill DP et al (2006) A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. Cancer Res 66:3987–3991
Hanawalt PC (2002) Subpathways of nucleotide excision repair and their regulation. Oncogene 21:8949–8956
Friedberg EC (2001) How nucleotide excision repair protects against cancer. Nat Rev Cancer 1:22–33
Khanna KK, Jackson SP (2001) DNA double-strand breaks: signaling, repair and the cancer connection. Nat Genet 27:247–254
Bakkenist CJ, Kastan MB (2003) DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 421:499–506
Waga S, Stillman B (1998) The DNA replication fork in eukaryotic cells. Annu Rev Biochem 67:721–751
Ding J, Miao ZH, Meng LH et al (2006) Emerging cancer therapeutic opportunities target DNA-repair systems. Trends Pharmacol Sci 27:338–344
Hegi ME, Diserens AC, Gorlia T et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997–1003
Bristow RG, Hill RP (2008) Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nat Rev Cancer 8:180–192
Sedelnikova OA, Bonner WM (2006) GammaH2AX in cancer cells: a potential biomarker for cancer diagnostics, prediction and recurrence. Cell Cycle 5:2909–2913
Thoms J, Bristow RG (2010) DNA repair targeting and radiotherapy: a focus on the therapeutic ratio. YSRAO 20:217–222
Brown JM, Wilson WR (2004) Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 4:437–447
Chan N, Koritzinsky M, Zhao H et al (2008) Chronic hypoxia decreases synthesis of homologous recombination proteins to offset chemoresistance and radioresistance. Cancer Res 68:605–614
Bindra RS, Schaffer PJ, Meng A et al (2004) Down-regulation of Rad51 and decreased homologous recombination in hypoxic cancer cells. Mol Cell Biol 24:8504–8518
Hegan DC, Lu Y, Stachelek GC et al (2010) Inhibition of poly(ADP-ribose) polymerase down-regulates BRCA1 and RAD51 in a pathway mediated by E2F4 and p130. Proc Natl Acad Sci USA 107:2201–2206
Chalmers AJ, Lakshman M, Chan N et al (2010) Poly(ADP-ribose) polymerase inhibition as a model for synthetic lethality in developing radiation oncology targets. Semin Radiat Oncol 20:274–281
Karran P, Marinus MG (1982) Mismatch correction at O6-methylguanine residues in E. coli DNA. Nature 296:868–869
Liu L, Markowitz S, Gerson SL (1996) Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-bis(2-chloroethyl)nitrosourea. Cancer Res 56:5375–5379
Hirose Y, Berger MS, Pieper RO (2001) p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells. Cancer Res 61:1957–1963
Esteller M, Garcia-Foncillas J, Andion E et al (2000) Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343:1350–1354
Marchesi F, Turriziani M, Tortorelli G et al (2007) Triazene compounds: mechanism of action and related DNA repair systems. Pharmacol Res Off J Ita Pharmacol Soc 56:275–287
Schwab M (2009) Encyclopedia of cancer, 2nd edn. Springer, New York
Liu L, Gerson SL (2006) Targeted modulation of MGMT: clinical implications. Clin Cancer Res 12:328–331
Adhikari S, Choudhury S, Mitra PS et al (2008) Targeting base excision repair for chemosensitization. Anticancer Agents Med Chem 8:351–357
Tang JB, Svilar D, Trivedi RN et al (2011) N-methylpurine DNA glycosylase and DNA polymerase beta modulate BER inhibitor potentiation of glioma cells to temozolomide. Neuro-oncology 13:471–486
Agnihotri S, Wolf A, Munoz DM et al (2011) A GATA4-regulated tumor suppressor network represses formation of malignant human astrocytomas. J Exp Med 208:689–702
Cheng CL, Johnson SP, Keir ST et al (2005) Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft. Mol Cancer Ther 4:1364–1368
Hall EJ, Giaccia AJ (2006) Radiobiology for the radiologist, 6th edn. Lippincott Williams & Wilkins, Philadelphia
Digweed M, Sperling K (2004) Nijmegen breakage syndrome: clinical manifestation of defective response to DNA double-strand breaks. DNA Repair (Amst) 3:1207–1217
Savitsky K, Bar-Shira A, Gilad S et al (1995) A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science 268:1749–1753
Stewart GS, Maser RS, Stankovic T et al (1999) The DNA double-strand break repair gene hMRE11 is mutated in individuals with an ataxia-telangiectasia-like disorder. Cell 99:577–587
Bao S, Wu Q, McLendon RE et al (2006) Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444:756–760
Kao GD, Jiang Z, Fernandes AM et al (2007) Inhibition of phosphatidylinositol-3-OH kinase/Akt signaling impairs DNA repair in glioblastoma cells following ionizing radiation. J Biol Chem 282:21206–21212
Mukherjee B, McEllin B, Camacho CV et al (2009) EGFRvIII and DNA double-strand break repair: a molecular mechanism for radioresistance in glioblastoma. Cancer Res 69:4252–4259
Toulany M, Rodemann HP (2010) Membrane receptor signaling and control of DNA repair after exposure to ionizing radiation. Nucl Med (Nuklearmedizin) 49(Suppl 1):S26–S30
Quinn JA, Desjardins A, Weingart J et al (2005) Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. J Clin Oncol 23:7178–7187
Quinn JA, Jiang SX, Reardon DA et al (2009) Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma. Cancer 115:2964–2970
Quinn JA, Jiang SX, Reardon DA et al (2009) Phase II trial of temozolomide plus O6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. J Clin Oncol 27:1262–1267
Quinn JA, Jiang SX, Reardon DA et al (2009) Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma. Neuro-oncology 11:556–561
Ranson M, Middleton MR, Bridgewater J et al (2006) Lomeguatrib, a potent inhibitor of O6-alkylguanine-DNA-alkyltransferase: phase I safety, pharmacodynamic, and pharmacokinetic trial and evaluation in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res 12:1577–1584
Bobola MS, Blank A, Berger MS et al (2001) Apurinic/apyrimidinic endonuclease activity is elevated in human adult gliomas. Clin Cancer Res 7:3510–3518
Silber JR, Bobola MS, Blank A et al (2002) The apurinic/apyrimidinic endonuclease activity of Ape1/Ref-1 contributes to human glioma cell resistance to alkylating agents and is elevated by oxidative stress. Clin Cancer Res 8:3008–3018
Bobola MS, Emond MJ, Blank A et al (2004) Apurinic endonuclease activity in adult gliomas and time to tumor progression after alkylating agent-based chemotherapy and after radiotherapy. Clin Cancer Res 10:7875–7883
Schreiber V, Dantzer F, Ame J-C et al (2006) Poly(ADP-ribose): novel functions for an old molecule. Nat Rev Mol Cell Biol 7:517–528
Johnson N, Li Y-C, Walton ZE et al (2011) Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition. Nature Med 17:875–882
Hochegger H, Dejsuphong D, Fukushima T et al (2006) Parp-1 protects homologous recombination from interference by Ku and Ligase IV in vertebrate cells. EMBO J 25:1305–1314
Wang M, Wu W, Wu W et al (2006) PARP-1 and Ku compete for repair of DNA double strand breaks by distinct NHEJ pathways. Nucleic Acids Res 34:6170–6182
Boulton S, Kyle S, Durkacz BW (1999) Interactive effects of inhibitors of poly(ADP-ribose) polymerase and DNA-dependent protein kinase on cellular responses to DNA damage. Carcinogenesis 20:199–203
Bowman KJ, White A, Golding BT et al (1998) Potentiation of anti-cancer agent cytotoxicity by the potent poly(ADP-ribose) polymerase inhibitors NU1025 and NU1064. Br J Cancer 78:1269–1277
Brock WA, Milas L, Bergh S et al (2004) Radiosensitization of human and rodent cell lines by INO-1001, a novel inhibitor of poly(ADP-ribose) polymerase. Cancer Lett 205:155–160
Calabrese CR, Almassy R, Barton S et al (2004) Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. J Natl Cancer Inst 96:56–67
Fernet M, Ponette V, Deniaud-Alexandre E et al (2000) Poly(ADP-ribose) polymerase, a major determinant of early cell response to ionizing radiation. Int J Radiat Biol 76:1621–1629
Noel G, Godon C, Fernet M et al (2006) Radiosensitization by the poly(ADP-ribose) polymerase inhibitor 4-amino-1,8-naphthalimide is specific of the S phase of the cell cycle and involves arrest of DNA synthesis. Mol Cancer Ther 5:564–574
Veuger SJ, Curtin NJ, Richardson CJ et al (2003) Radiosensitization and DNA repair inhibition by the combined use of novel inhibitors of DNA-dependent protein kinase and poly(ADP-ribose) polymerase-1. Cancer Res 63:6008–6015
Miknyoczki SJ, Jones-Bolin S, Pritchard S et al (2003) Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor. Mol Cancer Ther 2:371–382
Ratnam K, Low JA (2007) Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology. Clin Cancer Res 13:1383–1388
Yap T (2007) First in human phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of KU-0059436 (Ku), a small molecule inhibitor of poly ADP-ribose polymerase (PARP) in cancer patients (p), including BRCA1/2 mutation carriers. J Clin Oncol ASCO Annual Meeting Proceedings Part I 25
Dungey FA, Löser DA, Chalmers AJ (2008) Replication-dependent radiosensitization of human glioma cells by inhibition of poly(ADP-Ribose) polymerase: mechanisms and therapeutic potential. Int J Radiat Oncol Biol Phys 72:1188–1197
Miknyoczki S, Chang H, Grobelny J et al (2007) The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity. Mol Cancer Ther 6:2290–2302
Friedman HS, Johnson SP, Dong Q et al (1997) Methylator resistance mediated by mismatch repair deficiency in a glioblastoma multiforme xenograft. Cancer Res 57:2933–2936
Denny BJ, Wheelhouse RT, Stevens MF et al (1994) NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA. Biochemistry 33:9045–9051
Russo AL, Kwon H-C, Burgan WE et al (2009) In vitro and in vivo radiosensitization of glioblastoma cells by the poly (ADP-ribose) polymerase inhibitor E7016. Clin Cancer Res 15:607–612
McEllin B, Camacho CV, Mukherjee B et al (2010) PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors. Cancer Res 70:5457–5464
Mendes-Pereira AM, Martin SA, Brough R et al (2009) Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med 1:315–322
Nitta M, Kozono D, Kennedy R et al (2010) Targeting EGFR induced oxidative stress by PARP1 inhibition in glioblastoma therapy. PloS ONE 5:e10767
Bai RY, Staedtke V, Riggins GJ (2011) Molecular targeting of glioblastoma: drug discovery and therapies. Trends Mol Med 17:301–312
Shen WH, Balajee AS, Wang J et al (2007) Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell 128:157–170
Matsuoka S, Ballif BA, Smogorzewska A et al (2007) ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science 316:1160–1166
Chakravarti A, Zhai G, Suzuki Y et al (2004) The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas. J Clin Oncol 22:1926–1933
Network CGAR (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455:1061–1068
Parsons DW, Jones S, Zhang X et al (2008) An integrated genomic analysis of human glioblastoma multiforme. Science (New York, NY) 321:1807–1812
Ekstrand AJ, Longo N, Hamid ML et al (1994) Functional characterization of an EGF receptor with a truncated extracellular domain expressed in glioblastomas with EGFR gene amplification. Oncogene 9:2313–2320
Huang HS, Nagane M, Klingbeil CK et al (1997) The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. J Biol Chem 272:2927–2935
Nishikawa R, Ji XD, Harmon RC et al (1994) A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci USA 91:7727–7731
Golding SE, Morgan RN, Adams BR et al (2009) Pro-survival AKT and ERK signaling from EGFR and mutant EGFRvIII enhances DNA double-strand break repair in human glioma cells. Cancer Biol Ther 8:730–738
Mukherjee B, Choy H, Nirodi C et al (2010) Targeting nonhomologous end-joining through epidermal growth factor receptor inhibition: rationale and strategies for radiosensitization. YSRAO 20:250–257
Brown PD, Krishnan S, Sarkaria JN et al (2008) Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. J Clin Oncol 26:5603–5609
Peereboom DM, Shepard DR, Ahluwalia MS et al (2010) Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme. J Neurooncol 98:93–99
Prados MD, Chang SM, Butowski N et al (2009) Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. J Clin Oncol 27:579–584
Chen G, Yuan SS, Liu W et al (1999) Radiation-induced assembly of Rad51 and Rad52 recombination complex requires ATM and c-Abl. J Biol Chem 274:12748–12752
Slupianek A, Hoser G, Majsterek I et al (2002) Fusion tyrosine kinases induce drug resistance by stimulation of homology-dependent recombination repair, prolongation of G(2)/M phase, and protection from apoptosis. Mol Cell Biol 22:4189–4201
Russell JS, Brady K, Burgan WE et al (2003) Gleevec-mediated inhibition of Rad51 expression and enhancement of tumor cell radiosensitivity. Cancer Res 63:7377–7383
Geng L, Shinohara ET, Kim D et al (2006) STI571 (Gleevec) improves tumor growth delay and survival in irradiated mouse models of glioblastoma. Int J Radiat Oncol Biol Phys 64:263–271
Wen PY, Yung WKA, Lamborn KR et al (2006) Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin Cancer Res 12:4899–4907
Barker CA, Powell SN (2010) Enhancing radiotherapy through a greater understanding of homologous recombination. YSRAO 20:267–273 e263
Murakawa Y, Sonoda E, Barber LJ et al (2007) Inhibitors of the proteasome suppress homologous DNA recombination in mammalian cells. Cancer Res 67:8536–8543
Shi W, Ma Z, Willers H et al (2008) Disassembly of MDC1 foci is controlled by ubiquitin-proteasome-dependent degradation. J Biol Chem 283:31608–31616
Jacquemont C, Taniguchi T (2007) Proteasome function is required for DNA damage response and fanconi anemia pathway activation. Cancer Res 67:7395–7405
Kubicek GJ, Werner-Wasik M, Machtay M et al (2009) Phase I trial using proteasome inhibitor bortezomib and concurrent temozolomide and radiotherapy for central nervous system malignancies. Int J Radiat Oncol Biol Phys 74:433–439
Garber K (2005) New checkpoint blockers begin human trials. J Natl Cancer Inst 97:1026–1028
Lau CC, Pardee AB (1982) Mechanism by which caffeine potentiates lethality of nitrogen mustard. Proc Natl Acad Sci USA 79:2942–2946
Hirai H, Iwasawa Y, Okada M et al (2009) Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents. Mol Cancer Ther 8:2992–3000
Wang Y, Decker SJ, Sebolt-Leopold J (2004) Knockdown of Chk1, Wee1 and Myt1 by RNA interference abrogates G2 checkpoint and induces apoptosis. Cancer Biol Ther 3:305–313
Mizuarai S, Yamanaka K, Itadani H et al (2009) Discovery of gene expression-based pharmacodynamic biomarker for a p53 context-specific anti-tumor drug Wee1 inhibitor. Mol Cancer 8:34
Wang Y, Li J, Booher RN et al (2001) Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator. Cancer Res 61:8211–8217
Parker LL, Piwnica-Worms H (1992) Inactivation of the p34cdc2-cyclin B complex by the human WEE1 tyrosine kinase. Science 257:1955–1957
Watanabe N, Broome M, Hunter T (1995) Regulation of the human WEE1Hu CDK tyrosine 15-kinase during the cell cycle. EMBO J 14:1878–1891
Igarashi M, Nagata A, Jinno S et al (1991) Wee1(+)-like gene in human cells. Nature 353:80–83
Akinaga S, Nomura K, Gomi K et al (1993) Enhancement of antitumor activity of mitomycin C in vitro and in vivo by UCN-01, a selective inhibitor of protein kinase C. Cancer Chemother Pharmacol 32:183–189
Arlander SJ, Eapen AK, Vroman BT et al (2003) Hsp90 inhibition depletes Chk1 and sensitizes tumor cells to replication stress. J Biol Chem 278:52572–52577
Flatten K, Dai NT, Vroman BT et al (2005) The role of checkpoint kinase 1 in sensitivity to topoisomerase I poisons. J Biol Chem 280:14349–14355
Hirose Y, Berger MS, Pieper RO (2001) Abrogation of the Chk1-mediated G(2) checkpoint pathway potentiates temozolomide-induced toxicity in a p53-independent manner in human glioblastoma cells. Cancer Res 61:5843–5849
Mesa RA, Loegering D, Powell HL et al (2005) Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine. Blood 106:318–327
Shi Z, Azuma A, Sampath D et al (2001) S-phase arrest by nucleoside analogues and abrogation of survival without cell cycle progression by 7-hydroxystaurosporine. Cancer Res 61:1065–1072
Syljuasen RG, Sorensen CS, Nylandsted J et al (2004) Inhibition of Chk1 by CEP-3891 accelerates mitotic nuclear fragmentation in response to ionizing radiation. Cancer Res 64:9035–9040
Teng M, Zhu J, Johnson MD et al (2007) Structure-based design and synthesis of (5-arylamino-2H-pyrazol-3-yl)-biphenyl-2′,4′-diols as novel and potent human CHK1 inhibitors. J Med Chem 50:5253–5256
Tse AN, Rendahl KG, Sheikh T et al (2007) CHIR-124, a novel potent inhibitor of Chk1, potentiates the cytotoxicity of topoisomerase I poisons in vitro and in vivo. Clin Cancer Res 13:591–602
Wang GT, Li G, Mantei RA et al (2005) 1-(5-Chloro-2-alkoxyphenyl)-3-(5-cyanopyrazin-2-yl)ureas [correction of cyanopyrazi] as potent and selective inhibitors of Chk1 kinase: synthesis, preliminary SAR, and biological activities. J Med Chem 48:3118–3121
Wang Q, Fan S, Eastman A et al (1996) UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53. J Natl Cancer Inst 88:956–965
Hotte SJ, Oza A, Winquist EW et al (2006) Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers: a Princess Margaret Hospital Phase II Consortium study. Ann Oncol 17:334–340
Kortmansky J, Shah MA, Kaubisch A et al (2005) Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with Fluorouracil in patients with advanced solid tumors. J Clin Oncol 23:1875–1884
Lara PN Jr, Mack PC, Synold T et al (2005) The cyclin-dependent kinase inhibitor UCN-01 plus cisplatin in advanced solid tumors: a California cancer consortium phase I pharmacokinetic and molecular correlative trial. Clin Cancer Res 11:4444–4450
Sausville EA, Arbuck SG, Messmann R et al (2001) Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms. J Clin Oncol 19:2319–2333
Sampath D, Cortes J, Estrov Z et al (2006) Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial. Blood 107:2517–2524
Welch S, Hirte HW, Carey MS et al (2007) UCN-01 in combination with topotecan in patients with advanced recurrent ovarian cancer: a study of the Princess Margaret Hospital Phase II consortium. Gynecol Oncol 106:305–310
Jin P, Gu Y, Morgan DO (1996) Role of inhibitory CDC2 phosphorylation in radiation-induced G2 arrest in human cells. J Cell Biol 134:963–970
De Witt Hamer PC, Mir SE, Noske D et al (2011) WEE1 kinase targeting combined with DNA-damaging cancer therapy catalyzes mitotic catastrophe. an official journal of the American Association for Cancer Research, Clinical cancer research
Mir SE, De Witt Hamer PC, Krawczyk PM et al (2010) In silico analysis of kinase expression identifies WEE1 as a gatekeeper against mitotic catastrophe in glioblastoma. Cancer Cell 18:244–257
Fernet M, Mégnin-Chanet F, Hall J et al. (2009) Control of the G2/M checkpoints after exposure to low doses of ionising radiation: Implications for hyper-radiosensitivity. DNA Repair (Amst)
Edwards SL, Brough R, Lord CJ et al (2008) Resistance to therapy caused by intragenic deletion in BRCA2. Nature 451:1111–1115
Sakai W, Swisher EM, Karlan BY et al (2008) Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 451:1116–1120
Conflict of interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Alexander, B.M., Pinnell, N., Wen, P.Y. et al. Targeting DNA repair and the cell cycle in glioblastoma. J Neurooncol 107, 463–477 (2012). https://doi.org/10.1007/s11060-011-0765-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11060-011-0765-4